{"id":792135,"date":"2024-12-03T16:16:19","date_gmt":"2024-12-03T21:16:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/"},"modified":"2024-12-03T16:16:19","modified_gmt":"2024-12-03T21:16:19","slug":"bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/","title":{"rendered":"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ADELAIDE, Australia and CAMBRIDGE, Mass., Dec.  03, 2024  (GLOBE NEWSWIRE) &#8212; Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural \u201cPromising Targets\u201d session at the 63\u02b3\u1d48\u00a0Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ.<\/p>\n<p align=\"justify\">\n        <strong>Oral Presentation Details:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong>Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the \u03b17 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune Trial<br \/><strong>Presenter: <\/strong>Murray Stein, M.D., M.P.H.<br \/><strong>Session: <\/strong>Promising Targets<br \/><strong>Date and Time: <\/strong>December 8, 2024 at 3:00 pm<\/p>\n<p align=\"justify\">Following the meeting, the slides from the oral presentation will be available under the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ALtXUQh2k3wRjwCx9gstY2k-sB_YlbUKmgHvl1clArjagPUQYd0u1C-VPQjSpRZJuy4nHIcefCiiwMchSPO2jgZYXKQw1PrSPi1eJDOUp5_6KXKFd2jW3S83ty7F6zdN\" rel=\"nofollow\" target=\"_blank\">Publications<\/a> webpage of the Company\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>FOR FURTHER INFORMATION PLEASE CONTACT: <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:33%;width:33%;min-width:33%;vertical-align: top\">\n            <strong>General<\/strong><br \/>\n            <br \/>Rajeev Chandra <br \/>Company Secretary<br \/><a href=\"mailto:CoSec@bionomics.com.au\" rel=\"nofollow\" target=\"_blank\">CoSec@bionomics.com.au<\/a><\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;vertical-align: top\">\n            <strong>Investor Relations<\/strong><br \/>\n            <br \/>Kevin Gardner<br \/><a href=\"mailto:kgardner@lifesciadvisors.com\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<td style=\"max-width:34%;width:34%;min-width:34%;vertical-align: top\">\n            <strong>Investor Relations<\/strong><br \/>\n            <br \/>Chris Calabrese<br \/><a href=\"mailto:ccalabrese@lifesciadvisors.com\" rel=\"nofollow\" target=\"_blank\">ccalabrese@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Bionomics Limited<\/strong><br \/>\n        <br \/>Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the \u03b17 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck &amp; Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer\u2019s disease and other CNS conditions. Bionomics\u2019 pipeline also includes preclinical assets that target Kv3.1\/3.2 and Nav1.7\/1.8 ion channels being developed for CNS conditions of high unmet need. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6tVXMorRmjb0MgKFd1xLkp3HI44GWQfLmvADyphi847rhOcTkjvgSO6LG-p4s4AknGgLrGK4bjosFcxzQ7XAiv4V3EVbRzqZwDp6mTUfDcU=\" rel=\"nofollow\" target=\"_blank\">www.bionomics.com.au<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201cpotential,\u201d \u201ccontinue\u201d or \u201cproject\u201d or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company\u2019s private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company\u2019s expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company\u2019s business and other risks described in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company\u2019s Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics\u2019 filings with the SEC, copies of which are available from the SEC\u2019s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pYN9Ack7_Cux3E2CeVXT-E96LhWTE0aD-VCDtiL4O2xNF8Y4DW_TMch_X55SGW-cf0QteyhqCTV3pyGUU9IG6g==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>) and on Bionomics\u2019 website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6tVXMorRmjb0MgKFd1xLkp3HI44GWQfLmvADyphi844X_XbutPcRyLZ6lG9V_v7k2GC5TxrKA2ExPYu03nbR5XxakwGErnOjr5wu3vv2roA=\" rel=\"nofollow\" target=\"_blank\">www.bionomics.com.au<\/a>) under the heading \u201cInvestor Center.\u201d All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjYyYjdkZDQtNDg3Zi00MzIzLTllYmQtNDM2ZGMyNDVjZDI4LTEyNTU3MjQ=\/tiny\/Bionomics-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural \u201cPromising Targets\u201d session at the 63\u02b3\u1d48\u00a0Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ. Oral Presentation Details: Title: Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the \u03b17 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-792135","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural \u201cPromising Targets\u201d session at the 63\u02b3\u1d48\u00a0Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ. Oral Presentation Details: Title: Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the \u03b17 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune &hellip; Continue reading &quot;Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T21:16:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting\",\"datePublished\":\"2024-12-03T21:16:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/\"},\"wordCount\":727,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/\",\"name\":\"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=\",\"datePublished\":\"2024-12-03T21:16:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Market Newsdesk","og_description":"ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural \u201cPromising Targets\u201d session at the 63\u02b3\u1d48\u00a0Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ. Oral Presentation Details: Title: Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the \u03b17 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune &hellip; Continue reading \"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-03T21:16:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting","datePublished":"2024-12-03T21:16:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/"},"wordCount":727,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/","name":"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=","datePublished":"2024-12-03T21:16:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzQxNiM2NjIwODcwIzIyNDQxNzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=792135"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792135\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=792135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=792135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=792135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}